Objective Stenting of small coronary arteries has always been limited by high rates of restenosis, and restenosis has mainly been attributed to inflammatory reactions resulting in cell proliferation and intimal hyper- 
restenosis has mainly been attributed to inflammatory reactions resulting in cell proliferation and intimal hyperplasia. Based on our experience for several years, we retrospectively investigated the effect of hydrocortisone on reducing in-stent restenosis.
Patients and MethodsStudy population consisted of consecutive 166 patients, 221 lesions, who electively underwent stent implantations stent diameter less than 3 mminto coronary arteries between February 1999 and October 2002. Weintravenously administered hydrocortisone before the procedure to 40 patients for preventing allergic reactions due to contrast material, and the effect of hydrocortisone on reducing restenosis was retrospectively compared with 126 patients who did not receive this treatment.
Results There was no significant difference in the prevalence of diabetes mellitus, hyperlipidemia, or hypertension between the two groups. There was no significant difference in the type of lesion, length of stent, balloon/artery ratio, or initial success rate between the two groups, but stent diameter was significantly smaller in the hydrocortisone group compared with the control group. On six-month angiographic follow-up, the restenosis rate was significantly lower in the hydrocortisone group compared with the control group (16.2% vs 34.0%, respectively), and the target lesion revascularization rate was also significantly lower in the hydrocortisone group compared with the control group (13.2% vs 27.5 % , respectively). Conclusion These results suggest that intravenous administration of hydrocortisone reduces in-stent restenosis of small coronary arteries. Prospectively controlled trials
Introduction
Although percutaneous transluminal coronary angioplasty is widely accepted as an effective treatment in patients with coronary ischemia, it has always been limited by high rates of restenosis, reported in up to 40%of all treated lesions (1, 2) and half of treated lesions in small coronary arteries (3, 4). Coronary stenting reduced the rate of restenosis by approximately 10%, but, even today, the rate of restenosis remains at approximately 30%, and the rate of target lesion revascularization reaches approximately 20%of all treated lesions (2, (5) (6) (7) . Furthermore, the in-stent restenosis rate of small vessels has been reported to be 30.1 to 44%in the previous studies, and the restenosis rate gets higher as complex, restenotic, diabetic, or chronic total lesions are more included (8) (9) (10) (11) (12) .
Consequently, intensive passion has been generated for the search of methodsto solve this problem of in-stent restenosis. Tranilast (13-15), cilostazol (7), probucol Table 2 summarizes the baseline angiographic characteristics of the two groups. There was no significant difference in target vessels, types of target lesions, and the proportion of restenotic lesions or chronic total occlusive lesions between the two groups.
Procedural data
Early outcomes and procedural data are presented in Table 3 . There was no significant difference in the initial success rate and the occurrence of major adverse cardiac events in hospital between both groups. These results were thought to be compatible as the procedures by us, common interventionalists not of the special or first rank. At 6 months after the stentmg procedure, the restenosis rate was significantly lower in the hydrocortisone group than in the control group (16.2% vs 34.0%, respectively; p=0.007); likewise, the rate of target lesion revascularization was significantly lower in the hydrocortisone group (13.2% vs 27.5%, respectively; p=0.021).
Multiple regression analysis for determinants of instent restenosis Table 5 shows the results by analysis of the determination of independent factors for in-stent restenosis. Diabetes mellitus, administration of hydrocortisone, hyperlipidemia, patient's age, diameter of stent, length of stent, hypertension, and use of statins were selected for multiple regression analysis, and of these, diabetes mellitus and administration of hydrocortisone were independent factors related to instent restenosis. Diabetes mellitus was positively related to in-stent restenosis, and administration of hydrocortisone was negatively related to in-stent restenosis.
Discussion
Restenosis after coronary stenting is mainly caused by inflammatory reactions due to injury to the vascular wall, resulting in cell proliferation and intimal hyperplasia (27) (28) (29) (30) (31) (32) (33) , and the onset of these inflammatory reactions occurs soon after the procedure at the molecular level (33, 35-37), resulting in reactions at the cellular level within a few days (38). A recent report showed the important role of early inflammatory events in modulating the response to vascular injury in Restenosis Prevention by Hydrocortisone reported that glucocorticoids suppress inflammation-related factors in a rat or rabbit intimal injury models (47-49). Furthermore, hydrocortisone which is a rapid-and shortacting natural glucocorticoid suppresses the increase of nucleic acids and the angiogenesis related to cell proliferation and the progression of inflammatory reactions, and it increases the production of collagen fiber contributing to the stabilization of the vascular wall. In contrast, methylprednisolone which is a slow-and long-acting synthetic glucocorticoid does not do (50). Accordingly, adding the results of our investigation, we expect hydrocortisone to be more suitable among glucocorticoids for preventing resenosis after coronary stenting.
In the present study, the restenosis rate was significantly lower in the hydrocortisone group than in the control group (16.2% vs 34.0%, respectively). The rate of target lesion revascularization was also significantly lower in the hydrocortisone group than in the control group (13.2% vs 27.5%, respectively).
The restenosis rate has been reported to be 22% to 31% even in relatively easy STRESS or BENESTENT lesions (2, 5), and it has been reported to be 30.1% to 44.0% in the previous studies about stenting of small vessels (8-12).
Therefore, the restenosis rate and revascularization rate of target lesions in the control group of this study are thought to be acceptable, and the restenosis rate and revascularization rate of target lesions in the hydrocortisone group are thought to be rather low and favorable in small vessels. In the present study, only diabetes mellitus and administration of hydrocortisone were independent factors related to in-stent restenosis.
There was no significant difference of the prevalence of diabetes mellitus between the hydrocortisone group and the control group, and accordingly, favorable results in the hydrocortisone group are thought to be gained by the effect of hydrocortisone treatment.
Study Limitations
The retrospective design and the limited number of patients studied are obvious limitations of this study, and prospectively controlled trials will be necessary to confirm the e fficacy of hydrocortisone.
In spite of several limitations, we think that favorable and encouraging results are shown in the present report of instent restenosis, and we think that this observation is noteworthy and beneficial for the future of coronary intervention. 
